Adial clears manufacturing hurdle for AD04 alcohol-use disorder drug ahead of phase 3 trial

Adial Pharmaceuticals, the US clinical-stage biotech developing therapies for addiction disorders, has completed a demonstration manufacturing batch for its lead drug candidate AD04, clearing a technical prerequisite for the production of clinical and registration batches ahead of a planned phase 3 trial.

The Nasdaq-listed group, based in Glen Allen, Virginia, said the demonstration batch met the prespecified targets for dissolution, content uniformity and blend uniformity, and matched the dissolution profile of the earlier phase 2 batch. The result confirms a successful transfer of the AD04 manufacturing and analytical process to a new contract development and manufacturing organisation — a routine but high-stakes step in late-stage drug development, where process deviations can delay trials by months and inflate costs significantly.

AD04 is a genetically targeted serotonin-3 receptor antagonist in development as a treatment for alcohol use disorder in heavy-drinking patients who carry certain genotypes, which the company identifies using its proprietary diagnostic test. The drug previously showed encouraging results in the ONWARD phase 3 study, with reductions in drinking and no overt safety or tolerability concerns, though the programme has since required further development work to position it for a fresh phase 3 programme and eventual regulatory submission. The manufacturing data will feed into an update of the company's Investigational New Drug application with the US Food and Drug Administration.

Cary Claiborne, president and chief executive of Adial, said the result "positions Adial to effectively progress our plans for the planned clinical trial program" and would assist ongoing discussions with the regulator.

The milestone comes at a moment of growing interest in pharmacological treatments for addiction. Adial has also flagged the potential of AD04 in other addictive disorders including opioid use disorder, gambling and obesity — the latter a notable extension, given the growing research interest in the overlap between addiction biology and appetite regulation that has been prompted by the commercial success of GLP-1 receptor agonists such as semaglutide.

Alcohol use disorder remains a substantial unmet medical need, with few approved pharmacological options widely prescribed despite the size of the affected patient population. For Adial, a small-cap biotech dependent on access to capital markets to fund its pipeline, successful execution of the AD04 manufacturing and phase 3 process is central to preserving its commercial optionality and its ability to secure partnership or licensing deals around the asset.